Anatoly Dritschilo
Research Subjects
Anatoly Dritschilo has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Scott Grindrod
Oncology and
45 shared publications - Gaurav Bandi
Department of Urology, Georgetown University School of Medicine, Washington, District of Columbia
40 shared publications - Keith Kowalczyk
Department of Urology, Medstar Georgetown University Hospital, Washington, DC 20007, USA
40 shared publications - Ryan Hankins
Department of Urology, Georgetown University School of Medicine, Washington, District of Columbia
40 shared publications - Alejandro Villagra
Georgetown University, Lombardi Comprehensive Cancer Center
30 shared publications - Amrita K. Cheema
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, USA
29 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Overall and sub-cohort based longitudinal (24 hours to 24 months) test statistics for proteomics data set comparing each time post-RT to baseline for the prostate cancer cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Overall and sub-cohort based longitudinal (24 hours to 24 months) test statistics for proteomics data set comparing each time post-RT to baseline for the prostate cancer cohort.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Validation of metabolite identification using tandem mass spectrometry-based fragmentation matching.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Validation of metabolite identification using tandem mass spectrometry-based fragmentation matching.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Volcano plot showing significant dysregulation of plasma metabolites at 24 hours (Panel A), one month (Panel B), 3 months (Panel C) and six months (Panel D) as compared to baseline (pre-RT).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Volcano plot showing significant dysregulation of plasma metabolites at 24 hours (Panel A), one month (Panel B), 3 months (Panel C) and six months (Panel D) as compared to baseline (pre-RT).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Linear Mixed Effect Models analysis of proteomics data combining all time points post-RT.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Linear Mixed Effect Models analysis of proteomics data combining all time points post-RT.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Heatmap visualization of significantly dysregulated metabolites following RT.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Heatmap visualization of significantly dysregulated metabolites following RT.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Linear mixed effects model analysis of metabolomics data augments validation of immune response findings with proteomics.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Linear mixed effects model analysis of metabolomics data augments validation of immune response findings with proteomics.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Reactome based longitudinal pathway analysis showing significantly dysregulated pathways at 1 h, 24 hours, 1-, 3-, 6-, and 12-months following RT in the GU prostate cancer cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Reactome based longitudinal pathway analysis showing significantly dysregulated pathways at 1 h, 24 hours, 1-, 3-, 6-, and 12-months following RT in the GU prostate cancer cohort.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Test statistics comparing each post-RT time point to baseline (pre) in the GU cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Test statistics comparing each post-RT time point to baseline (pre) in the GU cohort.
- Open Access
- 1 December 2023
- Published by American Association for Cancer Research (AACR)
Data from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
Radiotherapy is a curative cancer treatment modality that imparts damage to cellular DNA, induces immunogenic cell death, and activates antitumor immunity. Despite the radiotherapy-induced direct antitumor effect seen within the treated volume, accumulating evidence indicates activation of innate antitumor immunity. Acute proinflammatory responses mediated by anticancer M1 macrophages are observed in the immediate aftermath following radiotherapy. However, after a few days, these M1 macrophages are converted to anti-inflammatory and pro-cancer M2 phenotype, leading to cancer resistance and underlying potential tumor relapse. Histone deacetylase 6 (HDAC6) plays a crucial role in regulating macrophage polarization and innate immune responses. Here, we report targeting HDAC6 function with a novel selective inhibitor (SP-2-225) as a potential therapeutic candidate for combination therapy with radiotherapy. This resulted in decreased tumor growth and enhanced M1/M2 ratio of infiltrating macrophages within tumors. These observations support the use of selective HDAC6 inhibitors to improve antitumor immune responses and prevent tumor relapse after radiotherapy.
- 1 December 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
Radiotherapy is a curative cancer treatment modality that imparts damage to cellular DNA, induces immunogenic cell death, and activates antitumor immunity. Despite the radiotherapy-induced direct antitumor effect seen within the treated volume, accumulating evidence indicates activation of innate antitumor immunity. Acute proinflammatory responses mediated by anticancer M1 macrophages are observed in the immediate aftermath following radiotherapy. However, after a few days, these M1 macrophages are converted to anti-inflammatory and pro-cancer M2 phenotype, leading to cancer resistance and underlying potential tumor relapse. Histone deacetylase 6 (HDAC6) plays a crucial role in regulating macrophage polarization and innate immune responses. Here, we report targeting HDAC6 function with a novel selective inhibitor (SP-2-225) as a potential therapeutic candidate for combination therapy with radiotherapy. This resulted in decreased tumor growth and enhanced M1/M2 ratio of infiltrating macrophages within tumors. These observations support the use of selective HDAC6 inhibitors to improve antitumor immune responses and prevent tumor relapse after radiotherapy.
- Open Access
- 1 December 2023
- Published by American Association for Cancer Research (AACR)
Data from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
Radiotherapy is a curative cancer treatment modality that imparts damage to cellular DNA, induces immunogenic cell death, and activates antitumor immunity. Despite the radiotherapy-induced direct antitumor effect seen within the treated volume, accumulating evidence indicates activation of innate antitumor immunity. Acute proinflammatory responses mediated by anticancer M1 macrophages are observed in the immediate aftermath following radiotherapy. However, after a few days, these M1 macrophages are converted to anti-inflammatory and pro-cancer M2 phenotype, leading to cancer resistance and underlying potential tumor relapse. Histone deacetylase 6 (HDAC6) plays a crucial role in regulating macrophage polarization and innate immune responses. Here, we report targeting HDAC6 function with a novel selective inhibitor (SP-2-225) as a potential therapeutic candidate for combination therapy with radiotherapy. This resulted in decreased tumor growth and enhanced M1/M2 ratio of infiltrating macrophages within tumors. These observations support the use of selective HDAC6 inhibitors to improve antitumor immune responses and prevent tumor relapse after radiotherapy.
- 1 December 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
Radiotherapy is a curative cancer treatment modality that imparts damage to cellular DNA, induces immunogenic cell death, and activates antitumor immunity. Despite the radiotherapy-induced direct antitumor effect seen within the treated volume, accumulating evidence indicates activation of innate antitumor immunity. Acute proinflammatory responses mediated by anticancer M1 macrophages are observed in the immediate aftermath following radiotherapy. However, after a few days, these M1 macrophages are converted to anti-inflammatory and pro-cancer M2 phenotype, leading to cancer resistance and underlying potential tumor relapse. Histone deacetylase 6 (HDAC6) plays a crucial role in regulating macrophage polarization and innate immune responses. Here, we report targeting HDAC6 function with a novel selective inhibitor (SP-2-225) as a potential therapeutic candidate for combination therapy with radiotherapy. This resulted in decreased tumor growth and enhanced M1/M2 ratio of infiltrating macrophages within tumors. These observations support the use of selective HDAC6 inhibitors to improve antitumor immune responses and prevent tumor relapse after radiotherapy.